Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: HER2 Positive Untreated Metastatic Breast Cancer|Asymptomatic or Low Symptomatic Brain Metastasis in Breast Cancer
Interventions: DRUG: Pertuzumab|DRUG: Trastuzumab
Sponsor: Kimberly Blackwell